Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS

Key Points

• Praxis Precision Medicines beat quarterly earnings estimates, reporting a loss of $2.87 per share versus the consensus estimate of a $3.67 loss.
• The company said its lead candidates, ulixacaltamide and relutrigine, remain on track for potential FDA decisions in late 2026 and early 2027, while commercial preparations are progressing ahead of possible launches.
• Pipeline risks remain: vormatrigine failed the primary endpoint in a focal-seizure trial, although Praxis plans to revise and restart follow-up studies. The company ended the quarter with $1.4 billion in cash and marketable securities, which it expects to fund operations into 2028.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($2.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.67) by $0.80, FiscalAI reports.

Here are the key takeaways from Praxis Precision Medicines' conference call:

• Ulixacaltamide and relutrigine remain on track for potential FDA decisions, with target dates around January 2027 and December 27, 2026, respectively. Praxis said neither program is expected to require an advisory committee meeting, and FDA mid-cycle reviews identified no significant efficacy issues.
• Praxis has substantially advanced its commercial preparations, including hiring and training the relutrigine field team, building the ulixacaltamide sales force, establishing distribution and supply networks, and developing patient-support programs. Management expects to be launch-ready ahead of the anticipated approvals.
• Enrollment in the EMERALD broad developmental and epileptic encephalopathy study exceeded its target at approximately 200 patients across more than 50 genetic etiologies. If positive, the company expects the data could support a supplemental filing for relutrigine in 2027.
• Vormatrigine’s POWER1 study failed its primary endpoint in highly refractory focal-onset seizures, although it met a key responder secondary endpoint. Praxis plans to amend POWER2 and POWER3 based on learnings about dose, treatment duration, and patient selection, with both studies expected to restart by the fourth quarter.
• Second-quarter operating expenses increased to $96.9 million and operating cash usage rose to $78 million, reflecting greater development and commercial spending. Praxis ended the quarter with $1.4 billion in cash and marketable securities, which management believes funds operations into 2028.

Praxis Precision Medicines Stock Performance

Shares of Praxis Precision Medicines stock traded up $50.93 on Thursday, hitting $370.16. The company had a trading volume of 1,507,115 shares, compared to its average volume of 320,663. Praxis Precision Medicines has a 1 year low of $37.19 and a 1 year high of $382.54. The stock has a 50 day moving average of $303.77 and a 200-day moving average of $315.47. The stock has a market capitalization of $10.32 billion, a price-to-earnings ratio of -27.69 and a beta of 2.78.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Piper Sandler reiterated an "overweight" rating on shares of Praxis Precision Medicines in a report on Monday, July 13th. BTIG Research restated a "buy" rating and set a $810.00 target price on shares of Praxis Precision Medicines in a research report on Wednesday, July 29th. Needham & Company LLC raised their target price on Praxis Precision Medicines from $575.00 to $582.00 and gave the stock a "buy" rating in a research note on Thursday. Robert W. Baird lowered their target price on Praxis Precision Medicines from $433.00 to $400.00 and set an "outperform" rating for the company in a report on Tuesday, June 2nd. Finally, TD Cowen restated a "buy" rating on shares of Praxis Precision Medicines in a report on Tuesday, June 2nd. Four analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Praxis Precision Medicines presently has an average rating of "Moderate Buy" and an average price target of $563.85.

Insider Transactions at Praxis Precision Medicines

In related news, Director Jill Desimone sold 11,600 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the completion of the sale, the director directly owned 2,337 shares of the company's stock, valued at approximately $727,554.84. This represents a 83.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.00% of the company's stock.

Institutional Trading of Praxis Precision Medicines

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its position in Praxis Precision Medicines by 24.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock worth $77,000 after acquiring an additional 359 shares during the period. Los Angeles Capital Management LLC bought a new stake in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $163,000. Norges Bank purchased a new stake in shares of Praxis Precision Medicines during the 2nd quarter valued at approximately $210,000. Commonwealth Equity Services LLC purchased a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at approximately $220,000. Finally, O Shaughnessy Asset Management LLC bought a new position in Praxis Precision Medicines in the 4th quarter worth approximately $226,000. 67.84% of the stock is owned by hedge funds and other institutional investors.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source